{"title":"Updated results from ASCENT-J02, a study of sacituzumab govitecan in Japanese participants with metastatic triple-negative breast cancer.","authors":"Nobuko Kawaguchi-Sakita, Yoichi Naito, Takanori Ishida, Takahiro Nakayama, Yutaka Yamamoto, Norikazu Masuda, Koji Matsumoto, Takahiro Kogawa, Kazuki Sudo, Akihiko Shimomura, Catherine Lai, Jiang Shao, Yuki Iwahori, Dianna Gary, Danh Huynh, Hiroji Iwata","doi":"10.1007/s10147-026-03214-9","DOIUrl":"https://doi.org/10.1007/s10147-026-03214-9","url":null,"abstract":"<p><strong>Background: </strong>Sacituzumab govitecan (SG) is approved in Japan for pretreated unresectable or recurrent triple-negative breast cancer (TNBC). ASCENT-J02 is an open-label, phase 1/2 study of SG in Japanese patients. At primary analysis (median follow-up, 6.1 months) of the metastatic TNBC (mTNBC) cohort (n = 36), objective response rate (ORR) was 25.0% (95% CI: 12.1-42.2; P = 0.0077), median progression-free survival (PFS) was 5.6 months (95% CI: 3.9-not reached), and SG had a manageable safety profile, consistent with the global phase 3 ASCENT study. We report updated outcomes, including the first overall survival (OS) results.</p><p><strong>Methods: </strong>Patients with pretreated mTNBC received 10 mg/kg SG intravenously on days 1 and 8 of 21-day cycles. The primary endpoint was independent review committee-assessed ORR (RECIST v1.1). Secondary endpoints included PFS, duration of response, time to response, OS, and safety.</p><p><strong>Results: </strong>With median follow-up of 15.9 months for 36 patients with mTNBC, ORR with SG was 31% (95% CI: 16-48); four complete responses were observed. Median PFS was 5.6 months (95% CI: 3.9-15.8), and median OS was 15.9 months (95% CI: 10.4-22.4). No treatment-emergent adverse events (TEAEs) led to treatment discontinuation or death. Grade ≥ 3 TEAEs were observed in 26 (72%) patients; most frequent were neutropenia (58%), leukopenia (36%), and diarrhea (11%).</p><p><strong>Conclusions: </strong>With longer follow-up, SG continued to demonstrate efficacy and safety consistent with the global ASCENT study. These results further support the use of SG in Japanese patients with pretreated mTNBC.</p>","PeriodicalId":13869,"journal":{"name":"International Journal of Clinical Oncology","volume":" ","pages":""},"PeriodicalIF":3.0,"publicationDate":"2026-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149405361","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Risk factors for pneumonitis development in patients with platinum-refractory head and neck cancer treated with salvage-line chemotherapy after nivolumab failure.","authors":"Ari Nishimura, Takane Watanabe, Hiroki Oka, Kengo Nagashima, Hideaki Nishi, Yoshihiko Kumai, Hiroaki Iijima, Kenji Okami, Yasushi Shimizu, Satoshi Kano, Kazue Ito, Tomoko Yamazaki, Hideaki Takahashi, Nobuhiko Oridate, Tomoya Yokota, Taiji Koyama, Naomi Kiyota, Yasuyoshi Sato, Shunji Takahashi, Kyoko Kato, Shigenori Kadowaki, Yoshitaka Honma","doi":"10.1007/s10147-026-03231-8","DOIUrl":"https://doi.org/10.1007/s10147-026-03231-8","url":null,"abstract":"<p><strong>Background: </strong>Immune checkpoint inhibitors (ICIs) have improved the survival of patients with recurrent or metastatic squamous cell carcinoma of the head and neck (RM-SCCHN), thus potentially enhancing the efficacy of subsequent salvage-line chemotherapy (SLC). However, ICIs can cause immune-related adverse events such as pneumonitis. Because SLC often includes potentially pneumotoxic agents, the risk of pneumonitis following ICI treatment is a clinical concern. Therefore, this study aimed to identify clinical risk factors for pneumonitis during SLC.</p><p><strong>Methods: </strong>This retrospective analysis included 244 patients from a previously published cohort (N = 480) who underwent SLC after platinum-based chemotherapy and nivolumab failure. Baseline characteristics and SLC regimens of patients with and without pneumonitis development were compared. Candidate risk factors included age 65 years or older, smoking history, prior cetuximab exposure, SLC regimen, renal dysfunction, baseline lung disease, and nivolumab-induced pneumonitis history.</p><p><strong>Results: </strong>Pneumonitis occurred in 12 (4.9%) patients during SLC (grade 1, n = 3; grade 2, n = 6; grade 3, n = 3). Treatment regimens included paclitaxel plus cetuximab (n = 3), taxane alone (n = 6), and S-1 (n = 3). A clear relationship between the treatment regimen and pneumonitis severity was not observed. In the univariate analysis, age 65 years or older and smoking history were significantly associated with pneumonitis, while a history of nivolumab-related pneumonitis was strongly associated with pneumonitis.</p><p><strong>Conclusion: </strong>Prior nivolumab-related pneumonitis was strongly associated with pneumonitis development during subsequent SLC and may be a clinically relevant risk factor for pulmonary toxicity in patients who received ICIs.</p>","PeriodicalId":13869,"journal":{"name":"International Journal of Clinical Oncology","volume":" ","pages":""},"PeriodicalIF":3.0,"publicationDate":"2026-11-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149386505","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Practical application and exploratory prognostic assessment of the FIGO 2023 stage IA3 criteria in endometrioid endometrial cancer with concurrent ovarian tumours.","authors":"Sari Takahashi, Tatsuyuki Chiyoda, Yumiko Kimura, Ayaka Sato, Daisuke Ochiai, Mitsuyo Jisaka, Tomomi Sakamaki, Shinya Oki, Kensuke Sakai, Tomoko Yoshihama, Wataru Yamagami","doi":"10.1007/s10147-026-03241-6","DOIUrl":"https://doi.org/10.1007/s10147-026-03241-6","url":null,"abstract":"<p><strong>Background: </strong>The FIGO 2023 classification introduced stage IA3 for synchronous low-grade endometrioid carcinoma of the uterus and ovary fulfilling four criteria; disease otherwise confined to these organs that fails any of them becomes stage IIIA1. How often the criteria are met, and how each relates to outcome, is unknown.</p><p><strong>Methods: </strong>We retrospectively studied 48 patients with concurrent endometrioid endometrial carcinoma and an ovarian tumour of borderline malignancy or higher. Pathology reports were re-abstracted for each criterion. The primary analysis was restricted to the 42 with an ovarian carcinoma, and each criterion was examined before and after restriction to low-grade histology.</p><p><strong>Results: </strong>Six of the 42 (14.3%) met all criteria; 12 (28.6%) would have qualified if unilateral FIGO 2014 stage I had been accepted in place of pT1a. Five of the 42 recurred. Endometrial grade 3 was associated with recurrence (five-year progression-free survival 25.0% versus 94.7%; hazard ratio 16.66, 95% CI 2.77-100.2, p = 0.002); ovarian histology was not significantly associated (p = 0.13). Direct extra-uterine/extra-ovarian extension was also associated with recurrence (hazard ratio 8.73, p = 0.018), but all three such recurrences had endometrial grade 3. One of the 31 with low-grade endometrioid carcinoma at both sites recurred. Thirty-four of 42 received adjuvant therapy.</p><p><strong>Conclusions: </strong>In this cohort, stage IA3 was uncommon once capsule status and cytology were assessed. Endometrial grade 3 was associated with recurrence, whereas the prognostic contribution of the individual anatomical criteria could not be determined because of the small number of events and confounding by adjuvant treatment. These observations are hypothesis-generating.</p>","PeriodicalId":13869,"journal":{"name":"International Journal of Clinical Oncology","volume":" ","pages":""},"PeriodicalIF":3.0,"publicationDate":"2026-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149370659","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Prognostic impact of primary Gleason pattern 5 in patients with low-volume metastatic hormone-sensitive prostate cancer treated with upfront ARPI-based doublet therapy: a real-world multicenter international collaborative study.","authors":"Yasutaka Yamada, Kodai Sato, Hao-Lun Luo, Hung-Jen Wang, Hui-Ying Liu, Yin-Lun Chang, Yu Li Su, Chun-Te Wu, Kai-Jie Yu, Po-Hung Lin, Chung-Yi Liu, Dong-Ru Ho, Yun-Ching Huang, Takuya Tsujino, Shinpei Saito, Ryoichi Maenosono, Kazuki Nishimura, Tatsuo Fukushima, Ko Nakamura, Satoshi Yamamoto, Takayuki Arai, Hiroaki Sato, Kosuke Higuchi, Akira Kurozumi, Akinori Takei, Manato Kanesaka, Keisuke Ando, Koichiro Kurokawa, Sanji Kanaoka, Nobushige Takeshita, Kei Yoneda, Daichi Hino, Takaaki Tamura, Tomokazu Sazuka, Yusuke Imamura, Kazuo Mikami, Kazuyoshi Nakamura, Satoshi Fukasawa, Yukio Naya, Maki Nagata, Atsushi Komaru, Toyofusa Tobe, Noriyuki Suzuki, Haruhito Azuma, Shinichi Sakamoto","doi":"10.1007/s10147-026-03240-7","DOIUrl":"https://doi.org/10.1007/s10147-026-03240-7","url":null,"abstract":"<p><strong>Background: </strong>Although androgen receptor pathway inhibitor (ARPI)-based doublet therapy is widely used for low-volume metastatic hormone-sensitive prostate cancer (mHSPC), clinical outcomes remain heterogeneous. We investigated prognostic factors in patients with low-volume de novo mHSPC treated with upfront ARPI-based doublet therapy.</p><p><strong>Methods: </strong>We retrospectively analyzed 289 patients with low-volume de novo mHSPC treated with upfront ARPI-based doublet therapy between 2018 and 2026. The primary endpoint was progression to castration-resistant prostate cancer (CRPC). Cancer-specific survival (CSS) and overall survival (OS) were secondary endpoints. An exploratory analysis compared achievement of prostate-specific antigen (PSA) ≤ 0.2 ng/mL between doublet and triplet therapy.</p><p><strong>Results: </strong>During a median follow-up of 24.6 months, 61 patients developed CRPC, 15 died from prostate cancer, and 26 died from any cause. Primary Gleason pattern 5 (GP5) was associated with CRPC progression in univariable analysis but not in multivariable analysis. Primary GP5 was independently associated with inferior CSS (hazard ratio [HR] 9.09, 95% confidence interval [CI] 2.85-34.87; P = 0.0002) and OS (HR 2.97, 95% CI 1.21-7.22; P = 0.0184), although these secondary findings were based on limited events. In exploratory analyses, triplet therapy was associated with higher odds of achieving PSA ≤ 0.2 ng/mL among patients with primary GP5-positive disease; however, the treatment-by-primary GP5 interaction was not significant (P for interaction = 0.4095).</p><p><strong>Conclusions: </strong>Primary GP5 was associated with unfavorable oncological outcomes in low-volume de novo mHSPC treated with upfront ARPI-based doublet therapy. Its prognostic significance and potential role in guiding treatment intensification require further validation.</p>","PeriodicalId":13869,"journal":{"name":"International Journal of Clinical Oncology","volume":" ","pages":""},"PeriodicalIF":3.0,"publicationDate":"2026-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149357398","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Self-reported eating speed and the risk of breast cancer among Japanese women: a retrospective cohort study from the LIFE Study.","authors":"Kengo Kawaguchi, Megumi Maeda, Futoshi Oda, Yasuharu Nakashima, Haruhisa Fukuda","doi":"10.1007/s10147-026-03237-2","DOIUrl":"https://doi.org/10.1007/s10147-026-03237-2","url":null,"abstract":"<p><strong>Background: </strong>Eating speed has been linked to higher body mass index and unfavorable metabolic profiles, but its association with incident breast cancer has not been well characterized.</p><p><strong>Methods: </strong>We conducted a retrospective cohort study using linked health check-up records and medical claims from 19 municipalities in the Longevity Improvement and Fair Evidence Study. Women aged ≥ 40 years who attended government-subsidized health check-ups (April 2016-March 2021) and answered an eating speed question were included. Eating speed was self-reported as faster, normal, or slower. Incident invasive breast cancer was identified using a validated claims-based algorithm. Cause-specific hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated using Cox proportional hazards models comparing faster and slower versus normal eating speed with stepwise adjustment for age, lifestyle factors, and comorbidities.</p><p><strong>Results: </strong>Among 243,737 women included in the analyses, 3213 (1.3%) developed breast cancer during follow-up. In the fully adjusted model, slower eating was associated with a lower risk of breast cancer compared with normal eating (HR 0.84, 95% CI 0.73-0.96), whereas faster eating showed no association (HR 1.02, 95% CI 0.93-1.10). The results were generally consistent across competing-risk and sensitivity analyses.</p><p><strong>Conclusion: </strong>In this large cohort, slower self-reported eating speed was associated with a modestly lower risk of incident breast cancer. By providing one of the first large-scale longitudinal evaluations of the association between self-reported eating speed and breast cancer risk, this study addresses a gap in epidemiological evidence but does not establish that slower eating prevents breast cancer.</p>","PeriodicalId":13869,"journal":{"name":"International Journal of Clinical Oncology","volume":" ","pages":""},"PeriodicalIF":3.0,"publicationDate":"2026-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149357400","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Prognostic impact of surgical resection after chemotherapy in oligometastatic versus non-oligometastatic gastric cancer.","authors":"Takaaki Arigami, Keishi Okubo, Masataka Shimonosono, Daisuke Matsushita, Masahiro Noda, Ken Sasaki, Kenji Baba, Yota Kawasaki, Takao Ohtsuka","doi":"10.1007/s10147-026-03238-1","DOIUrl":"https://doi.org/10.1007/s10147-026-03238-1","url":null,"abstract":"<p><strong>Background: </strong>Surgical resection following chemotherapy has been considered a potentially effective strategy for improving survival in patients with stage IV gastric cancer. Recently, the concept of oligometastasis has gained increasing attention. However, the prognostic significance of surgical resection according to oligometastatic status remains unclear, particularly in comparison with non-oligometastatic disease.</p><p><strong>Methods: </strong>We retrospectively reviewed 249 patients with stage IV gastric cancer who received systemic chemotherapy. Patients were classified into an oligometastatic group (n = 52) or a non-oligometastatic group (n = 197) based on the extent of distant metastases. Overall survival (OS) was analyzed according to metastatic status and the performance of surgical resection.</p><p><strong>Results: </strong>Surgical resection after chemotherapy was performed in 27 (52%) patients in the oligometastatic group and in 47 (24%) patients in the non-oligometastatic group, with a significantly higher rate of surgery in the oligometastatic group (p < 0.01). Median OS was significantly longer in the oligometastatic group than in the non-oligometastatic group (p < 0.01). OS was significantly better in patients who underwent surgery after chemotherapy than in those who did not (p < 0.01). However, among patients who underwent surgery, there was no significant difference in OS between the oligometastatic and non-oligometastatic groups (p = 0.29). Multivariate analysis identified peritoneal metastasis and surgical resection as independent prognostic factors (all p < 0.01).</p><p><strong>Conclusion: </strong>Favorable survival outcomes were observed in patients with oligometastatic gastric cancer and in selected patients with non-oligometastatic disease without peritoneal metastasis who underwent surgical resection after chemotherapy.</p>","PeriodicalId":13869,"journal":{"name":"International Journal of Clinical Oncology","volume":" ","pages":""},"PeriodicalIF":3.0,"publicationDate":"2026-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149357399","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Pharmacotherapy for older adults with cancer: a digest of the Japanese clinical practice guidelines (2nd edition) - lung cancer.","authors":"Toshio Kubo, Tomoya Shimokata, Yoko Tsukita, Kazuhisa Nakashima, Shoichiro Yamamoto, Nagio Takigawa, Fumio Nagashima, Ayumu Matsuoka, Hajime Asahina","doi":"10.1007/s10147-026-03242-5","DOIUrl":"https://doi.org/10.1007/s10147-026-03242-5","url":null,"abstract":"<p><strong>Background: </strong>The number of older adults with lung cancer is increasing in aging societies. However, determining optimal pharmacotherapy remains challenging because of heterogeneity in functional status, comorbidities, and the limited representation of older adults in clinical trials.</p><p><strong>Methods: </strong>This article presents an English digest of the second edition of the Japanese Clinical Practice Guidelines for Pharmacotherapy in Older Adults with Cancer, focusing on lung cancer. The guidelines were developed using the Minds 2020 methodology and incorporated systematic reviews, an evidence-to-decision framework, and multidisciplinary expert consensus.</p><p><strong>Results: </strong>These guidelines address key clinical questions in small-cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC), including prophylactic cranial irradiation, adjuvant therapy, and immune checkpoint inhibitor-based treatments. Most recommendations were conditional, and no recommendation could be made for several clinical questions because of limited evidence in older populations. Prophylactic cranial irradiation may reduce brain metastases in selected patients with SCLC but requires careful consideration of potential neurocognitive toxicity. In resected NSCLC, tegafur-uracil may be an option for selected older patients; however, evidence supporting platinum-based chemotherapy and immunotherapy remains insufficient. In advanced NSCLC, immune checkpoint inhibitor monotherapy may benefit selected patients, whereas the role of chemoimmunotherapy remains uncertain because of insufficient age-specific evidence.</p><p><strong>Conclusions: </strong>These guidelines provide practical, evidence-based recommendations for pharmacotherapy in older adults with lung cancer. They emphasize individualized treatment strategies based on patient characteristics, treatment goals, and tolerability. Further research in older populations is required to strengthen the evidence base for geriatric oncology.</p>","PeriodicalId":13869,"journal":{"name":"International Journal of Clinical Oncology","volume":" ","pages":""},"PeriodicalIF":3.0,"publicationDate":"2026-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149357397","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Interstitial lung disease in patients with recurrent and metastatic head and neck cancer treated with immune checkpoint inhibitors and cetuximab and/or paclitaxel.","authors":"Ryo Kawaura, Tomoya Yokota, Satoshi Hamauchi, Kunihiro Fushiki, Yusuke Onozawa, Shiori Aibara, Kayo Sakamoto, Nobuyuki Sakuma, Takashi Kojima, Shinya Morita, Takashi Mukaigawa, Hirofumi Ogawa, Tsuyoshi Onoe, Koiku Asakura, Masahiro Endo","doi":"10.1007/s10147-026-03244-3","DOIUrl":"https://doi.org/10.1007/s10147-026-03244-3","url":null,"abstract":"<p><strong>Background: </strong>In recurrent and metastatic head and neck cancer (R/M HNC), all of cetuximab (Cmab), paclitaxel (PTX), and immune checkpoint inhibitors (ICI) can cause interstitial lung disease (ILD). This study aimed to clarify the clinical outcome of ILD and risk factors for ILD.</p><p><strong>Methods: </strong>We retrospectively analyzed 400 patients with R/M HNC who initiated chemotherapy at our institution with any of ICI, Cmab, and PTX. The incidence of ILD induced by each drug, risk factors for ILD, and survival after ILD were evaluated. ILD was diagnosed by diagnostic radiologists.</p><p><strong>Results: </strong>The median follow-up period was 17.7 months. The incidence of ILD was 11.0% (20/182) in patients treated with both ICI and Cmab/PTX. Similarly, those of ILD were 8.8% (8/91) in the patients with ICI alone without Cmab/PTX, and 2.4% (3/127) in those of non-ICI. Multivariable analysis revealed that a history of heavy smoking (Brinkman index ≥ 600) (odds ratio [OR] 3.49, 95% confidence interval [CI] 1.21-10.1) was associated with ILD. 16 patients of ILD needed to change their regimen or withdraw chemotherapy. Nevertheless, the 5-year overall survival was higher in the ILD group than in the non-ILD group (25.1% vs. 5.7%, p = 0.0106).</p><p><strong>Conclusions: </strong>The incidence of ILD was higher in patients with R/M HNC who received ICI than in those who didn't. The history of heavy smoking was associated with ILD, and no significant association between treatment sequence of ICI plus Cmab and/or PTX and ILD incidence was observed.</p>","PeriodicalId":13869,"journal":{"name":"International Journal of Clinical Oncology","volume":" ","pages":""},"PeriodicalIF":3.0,"publicationDate":"2026-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149341980","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Circulating tumor DNA methylation and gut microbiota in colorectal cancer: diagnostic, prognostic, and therapeutic implications.","authors":"Kazuhito Sasaki, Shigenobu Emoto, Yuichiro Yokoyama, Soichiro Ishihara","doi":"10.1007/s10147-026-02966-8","DOIUrl":"10.1007/s10147-026-02966-8","url":null,"abstract":"<p><p>Colorectal cancer remains one of the leading causes of cancer-related mortality worldwide, and early detection is essential for improving outcomes. Advances in liquid biopsy technologies and microbiota research have shed new light on diagnostic and therapeutic strategies for colorectal cancer. Notably, circulating tumor DNA methylation has emerged as a sensitive and specific biomarker for early detection, recurrence surveillance, and treatment monitoring. Recent progress in methylation-based assays, including stool- and plasma-derived approaches, highlights their potential clinical utility; however, challenges remain in detecting minimal residual disease at the earliest stages. Parallel to these developments, the gut microbiota has been recognized as a critical modulator of colorectal carcinogenesis and treatment response. Specific bacterial species, such as Fusobacterium nucleatum, polyketide synthase-positive Escherichia coli, and enterotoxigenic Bacteroides fragilis, have been implicated in tumor initiation and progression through epigenetic reprogramming, including aberrant DNA methylation. Microbial metabolites, particularly short-chain fatty acids such as butyrate, influence DNA methyltransferase activity and histone modifications, linking microbial ecology to the host epigenome. Microbiota composition also affects responses to chemotherapy, radiotherapy, and immunotherapy, underscoring its potential as a predictive biomarker and therapeutic target. Integrating circulating tumor DNA methylation profiling with microbiota analysis provides a promising strategy for personalized colorectal cancer management, combining early detection with treatment outcome prediction. This review summarizes the current evidence and future directions at the interface of DNA methylation and the gut microbiota, emphasizing their synergistic role as composite biomarkers in precision oncology.</p>","PeriodicalId":13869,"journal":{"name":"International Journal of Clinical Oncology","volume":" ","pages":"2546-2555"},"PeriodicalIF":3.0,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13710455/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146040976","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Proteinuria as the cause of early dose modification in Japanese patients with metastatic colorectal cancer treated with fruquintinib: a multicenter real-world study.","authors":"Shohei Udagawa, Chihiro Ishizuka, Hiroki Osumi, Toshiharu Hirose, Natsuko Okita, Hidekazu Hirano, Hirokazu Shoji, Ken Kato, Koichiro Yoshino, Keitaro Shimozaki, Shota Fukuoka, Takeru Wakatsuki, Mariko Ogura, Akira Ooki, Keisho Chin, Kensei Yamaguchi, Atsuo Takashima, Eiji Shinozaki","doi":"10.1007/s10147-026-03181-1","DOIUrl":"10.1007/s10147-026-03181-1","url":null,"abstract":"<p><strong>Background: </strong>Fruquintinib has demonstrated survival benefits in patients with previously treated metastatic colorectal cancer (mCRC) in phase III trials. However, real-world data in Japanese patients remain limited. This study evaluated the effectiveness and safety of fruquintinib in routine clinical practice.</p><p><strong>Methods: </strong>We conducted a retrospective observational study at two cancer centers. Patients treated with fruquintinib for mCRC between November 2024 and December 2025 were included. Clinical outcomes and safety were evaluated, and exploratory analyses were performed according to starting dose, relative dose intensity (RDI), and selected adverse events (AEs).</p><p><strong>Results: </strong>A total of 92 patients were included. Fruquintinib was initiated at 5 mg in 72 patients (78.3%) and at 4 mg in 19 patients (20.7%). The disease control rate was 37.4%, and no objective responses were observed. Median time to treatment failure was 2.57 months (95% confidence interval [CI], 2.23-3.33), and median overall survival was 8.83 months (95% CI, 7.46-not estimable). The median follow-up period was 5.48 months. Grade ≥ 3 AEs occurred in 39 patients (42.4%), and treatment discontinuation due to AEs occurred in 4 patients (4.3%). Proteinuria was the leading cause of early dose reduction, with 39.1% of dose modifications occurring within 28 days. In exploratory analyses, no clear differences in outcomes were observed according to starting dose, RDI, hypertension, or proteinuria.</p><p><strong>Conclusions: </strong>Fruquintinib demonstrated feasible effectiveness and manageable toxicity in Japanese patients with mCRC. Proteinuria was a major determinant of treatment feasibility and frequently led to early dose modification.</p>","PeriodicalId":13869,"journal":{"name":"International Journal of Clinical Oncology","volume":" ","pages":"2720-2729"},"PeriodicalIF":3.0,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13710609/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148840071","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}